- Home
- CCEL vs LVTX Comparison
CCEL vs LVTX Comparison
Compare CCEL & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- LVTX
- Stock Information
- Founded
- CCEL 1989
- LVTX 2016
- Country
- CCEL United States
- LVTX Netherlands
- Employees
- CCEL N/A
- LVTX N/A
- Industry
- CCEL Managed Health Care
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- LVTX Health Care
- Exchange
- CCEL Nasdaq
- LVTX Nasdaq
- Market Cap
- CCEL 39.9M
- LVTX 33.9M
- IPO Year
- CCEL 1997
- LVTX 2021
- Fundamental
- Price
- CCEL $5.10
- LVTX $1.31
- Analyst Decision
- CCEL Strong Buy
- LVTX Hold
- Analyst Count
- CCEL 1
- LVTX 3
- Target Price
- CCEL $8.50
- LVTX $1.75
- AVG Volume (30 Days)
- CCEL 14.7K
- LVTX 13.4K
- Earning Date
- CCEL 07-14-2025
- LVTX 08-19-2025
- Dividend Yield
- CCEL 19.65%
- LVTX N/A
- EPS Growth
- CCEL N/A
- LVTX N/A
- EPS
- CCEL 0.01
- LVTX N/A
- Revenue
- CCEL $32,102,750.00
- LVTX $4,990,000.00
- Revenue This Year
- CCEL $2.49
- LVTX N/A
- Revenue Next Year
- CCEL $0.95
- LVTX N/A
- P/E Ratio
- CCEL $563.74
- LVTX N/A
- Revenue Growth
- CCEL 2.33
- LVTX N/A
- 52 Week Low
- CCEL $4.75
- LVTX $0.85
- 52 Week High
- CCEL $9.43
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- CCEL 48.43
- LVTX 50.22
- Support Level
- CCEL $5.00
- LVTX $1.27
- Resistance Level
- CCEL $6.35
- LVTX $1.33
- Average True Range (ATR)
- CCEL 0.29
- LVTX 0.04
- MACD
- CCEL 0.01
- LVTX -0.00
- Stochastic Oscillator
- CCEL 7.33
- LVTX 35.71
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.